Immunovant Inc (IMVT) Shares Outstanding 2018–TTM

Name: Immunovant Inc (IMVT) shares outstanding history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-10

Immunovant Inc annual shares outstanding for fiscal TTM was 206 million shares, an increase of 13.2% from 182 million shares in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

IMVT Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-12-31	2018-03-31
Shares Outstanding (M)	206M	182M	152M	138M	123M	110M	88M	43M	14M	—	10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMVT Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Shares Outstanding (M)	206M	204M	182M	174M	171M	152M	147M	146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

IONS Shares Outstanding — Ionis Pharmaceuticals Inc
SYRE Shares Outstanding — Spyre Therapeutics Inc.
CRNX Shares Outstanding — Crinetics Pharmaceuticals Inc
PCVX Shares Outstanding — Vaxcyte Inc
IBRX Shares Outstanding — Immunitybio Inc
TGTX Shares Outstanding — TG Therapeutics Inc

More IMVT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All IMVT financial statements → Interactive IMVT charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.